All analyses
7 min read

Last updated:

Sarcopenia: data and practical levers to preserve muscle after 40

Sarcopenia affects about one adult in six after 60, and muscle decline begins well before that. Prevalence, screening thresholds, strength and protein: what the studies allow us to state, and how to turn it into a measurable action plan.

8 studies citedsee the sources

Benjamin Sant

Co-founder of the School of Longevity

Strength training with dumbbells
Strength training with dumbbells

Sarcopenia combines loss of muscle mass and loss of muscle strength

Sarcopenia combines a loss of muscle mass, a fall in muscle strength and a reduction in physical performance. The 2019 European consensus describes two phenotypes, depending on whether the loss of mass remains proportional to the decline in strength. When strength falls while mass is preserved, the problem lies in tissue quality and motor unit recruitment. This phenotype is common: a substantial share of affected people have normal mass with insufficient strength. Skeletal muscle is therefore an organ whose function matters more than its appearance.

After the thirties, protein synthesis responds less to the same mechanical or nutritional stimulus: this is anabolic resistance. Strength per unit of cross-section falls first, before volume is lost. Muscle mass declines by 0.5 to 1% a year after 30, a slope that steepens clearly after 60. Women see a marked acceleration after menopause, with a greater loss than men of the same age. Grip strength drops earlier and faster in women. That gap has direct consequences for the screening thresholds used.

Sarcopenia sits within a trajectory in which fat mass rises, often from the forties onward, at stable weight. Abdominal adipose tissue releases fatty acids that feed low-grade inflammation and insulin resistance. Waist circumference tracked over time is more informative than weight alone. Unintentional weight loss, or difficulty climbing a flight of stairs, should lead to a medical assessment.

Grip strength declines earlier and faster than mass measured by bioimpedance: measuring function matters more than the body composition number.

Sarcopenia prevalence rises from the forties and peaks after 80

Measured on strength and mass, the prevalence of sarcopenia lies between 5 and 13% between 60 and 70, then reaches 11 to 50% after 80. These figures vary with the criteria used and the population. Risk increases year after year, and a hospital stay or corticosteroid treatment can trigger a rapid loss out of proportion to age. In younger people, the decline is slower and largely tied to inactivity.

Muscle strength is associated with all-cause mortality in large independent cohorts. Muscle mass index has been proposed as a predictor of longevity, with an increased risk of death when its value is low. These findings are observational and do not prove that increasing muscle tissue would reduce mortality. Muscle serves as a protein reservoir, a site of glucose disposal and a source of anti-inflammatory molecules.

Loss of muscle quality precedes loss of mass, which changes how we monitor. In the Health ABC study, lower strength and muscle quality were associated with higher mortality after 70. A stable weight and a preserved silhouette are therefore not grounds for reassurance. Immobilization is the most brutal and most underestimated factor. Bed rest costs 0.5 to 1% of muscle mass per week, and up to 15% of strength in two to three weeks of strict immobilization. That loss is largely reversible if mobilization resumes early, but returning to the initial level takes several weeks.

Three measurements under a minute are enough to screen for sarcopenia

Sarcopenia screening rests on a trio of simple, reproducible, low-cost tests. Grip strength, 4 m walking speed and chair-stand time form the minimal core. They require neither heavy equipment nor a specific setting and remain usable in consultation, in physiotherapy and at home. Screening does not replace diagnosis; its main value is to act before autonomy is lost.

Handgrip dynamometry is reproducible under the same conditions: dominant hand, arm extended at the edge of the table, two or three trials with the best retained. In older adults, the most used thresholds are below 27 kg in men and 16 kg in women. A walking speed below 0.8 m per second over 4 m points to functional decline and a raised risk of falls. Five repeated chair stands taking more than 12 seconds signal lower limb weakness. Every measurement is repeated twice, because execution error often exceeds the effect being sought.

The Short Physical Performance Battery combines several tests into a score from 0 to 10. A drop of two points in twelve months should alert the team, even if the absolute score remains correct. Connected devices do not measure strength, but walking about and inactivity give a useful indirect signal. They also document sleep duration, which conditions muscle recovery. The markers used in a consultation complete these data. The most useful remains the initial measurement, a 90-day plan, then remeasurement of the same tests. Without a quantified starting point, no progress can be set against the person themselves.

Quantified markers for screening, monitoring and risk factors in sarcopenia
MeasurementAlert thresholdReading of the result
Grip strengthBelow 27 kg in men, 16 kg in womenWeakness objectified
Grip strength at twelve monthsDrop greater than 10%Rapid loss to be addressed
4 m walking speedBelow 0.8 m per secondFunctional decline, fall risk
Five chair standsMore than 12 secondsLower limb weakness
SPPB scoreBelow 10 out of 10Reduced mobility
Muscle massDrop greater than 1% a year after 60Read with strength, never alone
Waist circumferenceIncrease at constant weightRedistribution of tissue
Bed rest or strict restLoss of 0.5 to 1% of mass per weekImmobilization, aggravating factor
Protein intakeBelow 0.8 g per kilogram per dayRisk of muscle undernutrition
SleepLess than six hours a night, chronicallyReduced muscle recovery
Sleep apneaMore than five respiratory events per hourFragmentation and lowered strength
Physical activityLess than 150 moderate minutes a weekLoss of function and mass
Women after menopauseGreater loss than men of the same ageThresholds to read differently

Quantified markers for screening, monitoring and risk factors in sarcopenia

Remeasurement of grip strength during a follow-up consultation
A quantified baseline obtained under the same conditions serves as the reference from one consultation to the next.

Protein and aging: the best documented nutritional lever

Protein intake is the best documented nutritional lever for limiting muscle tissue loss. International recommendations put the target for older adults between 1.0 and 1.2 g per kilogram per day, against 0.8 to 1.0 g in adults. A higher dose, close to 1.2 to 1.6 g per kilogram, is proposed during energy restriction or rehabilitation. The Morton meta-analysis confirms a dose-response effect of supplementation on gains from resistance training. That effect remains strongly conditioned by the starting training level.

Distribution matters as much as the total: at least 0.4 g per kilogram, spread over two or three servings. Concentrating intake in a single evening meal stimulates synthesis without increasing the final result. That supplement is relevant only if the base intake is insufficient or the training load is high. Aiming for 25 to 30 g per meal remains the simplest rule to apply.

In undernourished people, insufficient energy intake takes precedence over the amount of protein. Vitamin D, often deficient after 60, worsens muscle weakness and should be corrected. Milk, eggs, fish, meat and legumes cover the target without added supplements. Observing actual intake over three ordinary days is more informative than a theoretical estimate.

Resistance training raises muscle strength from two sessions a week

Resistance training remains the most effective intervention against loss of tissue and function. Meta-analyses show that strength gains increase with load, repetitions and session frequency. Two weekly sessions are enough in inactive adults, a third adding an advantage only if it is sustained over time. Dose-response relationships show a plateau beyond 60 to 70 minutes per session for strength, but not for mass. A stronger muscle also improves glucose metabolism and bone density.

Session content adapts to the starting point, which determines adherence. Chair stands, pushing off the hands and stair climbing produce durable results in sedentary people. A few dumbbells or elastic bands are enough to start, with no gym equipment. Progression stays slow, load increasing only while technique is controlled. The usual range is eight to twelve repetitions, for two to three sets per movement.

The effect appears within short time frames, which helps motivation. The first strength gains appear in four to eight weeks in most adults who were previously inactive. Recovery matters as much as effort: short sleep, pain or insufficient food cancel part of the gain. Walking work, often in short intervals, completes the program without excessive volume. Stopping for several days costs part of the gains. Measuring strength every three months secures follow-up and adjusts load.

Assessment of upper limb strength in a patient
Two progressive weekly sessions are enough to produce a measurable strength gain in inactive adults.

Ninety-day follow-up turns a recommendation into a measurable trajectory

For the professional supporting adults from 40 to 80, method matters as much as the result. A quantified baseline, obtained with the three reference tests, opens the consultation on facts. It records grip strength, walking speed and chair-stand time, with date and measurement conditions. Someone who says they have been weaker for a year thus gives a number to verify.

The plan is formulated with the person, around two or three realistic goals rather than an ideal list. One strength goal, one protein meal goal and one consistency goal structure the quarter. Order matters: training load first, protein next, sleep as a corrective marker. Markers of time, load and frequency make execution checkable. The usual obstacles, pain, fatigue, travel or lack of time, are prepared in advance. Real availability, measured in minutes per week, secures frequency.

Remeasuring the same tests at 90 days closes the loop and objectifies the strength gain. A drop of more than 10% on one of the tests between two measurements justifies medical investigation. The SPPB score, calculated once a year, offers a composite indicator of trajectory. Beyond six months, comparison between two functional assessments becomes the reference tool for long-term follow-up.

Ninety-day follow-up action plan established with the person
A quantified baseline, two or three goals and a remeasurement at 90 days make follow-up legible.

Sources

  1. 1.Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019.
  2. 2.Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014.
  3. 3.Borde R, Hortobágyi T, Granacher U. Dose-response relationships of resistance training in healthy old adults. Sports Med. 2015.
  4. 4.Morton RW, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains. Br J Sports Med. 2018.
  5. 5.Goodpaster BH, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med Sci. 2006.
  6. 6.Shen Y, et al. Exercise for sarcopenia in older people: a systematic review and network meta-analysis. J Cachexia Sarcopenia Muscle. 2023.
  7. 7.Nunes EA, et al. Systematic review and meta-analysis of protein intake to support muscle mass and function in healthy adults. J Cachexia Sarcopenia Muscle. 2022.
  8. 8.Zanker J, et al. Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand. J Cachexia Sarcopenia Muscle. 2023.

Reading studies is one thing, turning them into a plan is another

The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.

See the certification

11 modules, €2,200. Enrol

Benjamin Sant

Co-founder of the School of Longevity

Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.

This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.